We are live on ! Find out more
SRPT icon

Sarepta Therapeutics
SRPT

177 hedge funds and large institutions have $1.08B invested in Sarepta Therapeutics in 2016 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

72.29% more ownership

Funds ownership: 0% → 72.29% (+72%)

17% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 54

9% more call options, than puts

Call options by funds: $212M | Put options by funds: $195M

5% less funds holding

Funds holding: 186 → 177 (-9)

14% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 50

58% less capital invested

Capital invested by funds: $2.59B → $1.08B (-$1.51B)

64% less funds holding in top 10

Funds holding in top 10: 11 → 4 (-7)

Holders
177
Holders Change
-9
Holders Change %
-4.84%
% of All Funds
4.42%
Holding in Top 10
4
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-63.64%
% of All Funds
0.1%
New
43
Increased
63
Reduced
54
Closed
50
Calls
$212M
Puts
$195M
Net Calls
+$17.1M
Net Calls Change
+$274M

Top Buyers

1
CC
Carlson Capital
Texas
+$88.5M
2
SM
Sabby Management
Florida
+$59.4M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$27.9M
4
BFA
BlackRock Fund Advisors
California
+$21.6M
5
CCM
Cadian Capital Management
New York
+$14M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$77M
2
Millennium Management
Millennium Management
New York
-$64.8M
3
JG
Jefferies Group
New York
-$59.3M
4
RG
Redmile Group
California
-$39.3M
5
Jennison Associates
Jennison Associates
New York
-$33.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
FPF
176
FNY Partners Fund
New York
$156 +$229K +5,700 New
RG
177
Redmile Group
California
– -$39.3M -640,400 Closed
Lord, Abbett & Co
178
Lord, Abbett & Co
New Jersey
– -$18.6M -302,070 Closed
PC
179
PointState Capital
New York
– -$16.6M -270,000 Closed
O
180
OrbiMed
New York
– -$16.1M -261,800 Closed
Tudor Investment Corp
181
Tudor Investment Corp
Connecticut
– -$13.3M -215,933 Closed
GTC
182
Ghost Tree Capital
New York
– -$6.02M -150,000 Closed
DCM
183
Dialectic Capital Management
Connecticut
– -$4.82M -78,408 Closed
MCM
184
Moore Capital Management
New York
– -$4.3M -70,000 Closed
EI
185
EAM Investors
California
– -$3.51M -57,186 Closed
ACP
186
Acuta Capital Partners
California
– -$2.01M -50,000 Closed
IHM
187
Iguana Healthcare Management
New York
– -$3.07M -50,000 Closed
Wolverine Trading
188
Wolverine Trading
Illinois
– -$1.74M -43,206 Closed
PVI
189
Pura Vida Investments
New York
– -$2.46M -40,000 Closed
NIP
190
Nicholas Investment Partners
California
– -$2.37M -38,504 Closed
WC
191
Wexford Capital
Florida
– -$2.36M -38,460 Closed
DCM
192
Driehaus Capital Management
Illinois
– -$2.29M -37,375 Closed
Janus Henderson Group
193
Janus Henderson Group
United Kingdom
– -$2.15M -35,000 Closed
Parallax Volatility Advisers
194
Parallax Volatility Advisers
California
– -$1.1M -27,349 Closed
MAP
195
Moody Aldrich Partners
Massachusetts
– -$1.23M -20,085 Closed
TI
196
Trexquant Investment
Connecticut
– -$1.15M -18,700 Closed
GA
197
Geneva Advisors
Illinois
– -$1.08M -17,615 Closed
EMG
198
Ellington Management Group
Connecticut
– -$866K -14,100 Closed
Wellington Management Group
199
Wellington Management Group
Massachusetts
– -$831K -13,526 Closed
ARTA
200
A.R.T. Advisors
New York
– -$700K -11,400 Closed
6 7
8
9 10

SRPT Hedge Fund Activity: Q4 2016 in Review

177 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2016, worth a combined $1.08B — down 58% from $2.59B a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of SRPT and 43 opened new positions — a net loss of 7 holders — while 54 trimmed existing stakes and 63 added.

The largest buyer was Carlson Capital, opening a new position worth an estimated $88.5M. The largest seller was Point72 Asset Management, cutting an estimated $77M.

  • 177 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2016, down from 186 in Q3 2016.
  • Funds reported $1.08B of Sarepta Therapeutics stock for Q4 2016, down 58% quarter-over-quarter.
  • 43 funds opened new Sarepta Therapeutics positions in Q4 2016 and 50 closed out, a net change of -7 holders.
  • The largest Sarepta Therapeutics buyer in Q4 2016 was Carlson Capital, an estimated $88.5M added.
  • The largest Sarepta Therapeutics seller in Q4 2016 was Point72 Asset Management, an estimated $77M sold.

Based on aggregated 13F filings for Q4 2016.